

Appendix C.

SEQUENCE LISTING

```
<110> Hammer, Robert P.
       Fu, Yanwen
       Aucoin, Jed P.
       Miller, Tod J.
       McLaughlin, Mark L.
       McCarley, Robin L.
<120> Anti-fibril Peptides
<130> 0212.1 Hammer
<140> 10/666,095
<141> 2003-09-18
<150> 60/412,081
<151> 2002-09-19
<160> 17
<170> PatentIn version 3.2, WordPerfect 10
<210> 1
<211> 5
<212> PRT
<213> Homo sapiens
<400> 1
Lys Leu Val Phe Phe
<210> 2
<211> 4
<212> PRT
<213> Homo sapiens
<400> 2
Lys Leu Val Phe
```

<210> 3

1

<211> 6

<212> PRT

```
Homo sapiens
<213>
<400> 3
Lys Leu Val Phe Phe Ala
<210> 4
<211>
      12
<212>
      PRT
<213>
       artificial sequence
<220>
<223> Designed peptide. This is an engineered modification of SEQ
ID
       NO: 3, which is in turn derived from Homo sapiens.
<220>
<221> MISC_FEATURE
<222>
      (2)..(2)
      X in position 2 is C-alpha, alpha-diisobutylglycine.
<223>
<220>
<221> MISC FEATURE
<222>
      (4)..(4)
<223>
      X in position 4 is C-alpha, alpha-dibenzylglycine.
<220>
<221>
      MISC FEATURE
<222>
      (6)..(6)
       X in position 6 is C-alpha, alpha-dipropylglycine.
<223>
<220>
<221>
      MISC FEATURE
<222>
      (12)..(12)
<223>
       The Lys in position twelve is in amide form.
<400>
      4
Lys Xaa Val Xaa Phe Xaa Lys Lys Lys Lys Lys
                5
                                    10
<210>
      5
<211>
      12
<212>
      PRT
```

artificial sequence

<213>

```
<220>
<223> Designed peptide. This is an engineered modification of SEQ
ID
       NO: 3, which is in turn derived from Homo sapiens.
<220>
<221> misc feature
<222>
      (8)..(8)
       Xaa in position eight denotes
C-alpha, alpha-diisobutylglycine.
<220>
<221> misc feature
<222> (10)..(10)
<223> Xaa in position ten denotes C-alpha, alpha-dibenzylglycine.
<220>
<221> misc feature
<222> (12)..(12)
<223>
       Xaa in position twelve denotes C-alpha, alpha-dipropylglycine
       amide.
<400> 5
Lys Lys Lys Lys Lys Xaa Val Xaa Phe Xaa
<210> 6
<211> 7
<212> PRT
<213> Artificial sequence
<220>
<223>
      Designed peptide. This is an engineered modification of SEQ
ID
       NO: 3, which is in turn derived from Homo sapiens.
<220>
<221>
      misc feature
<222> (2)..(2)
<223>
      Xaa in position two denotes C-alpha, alpha-diisobutylqlycine.
<220>
<221>
      misc feature
<222> (4)..(4)
      Xaa in position four denotes C-alpha, alpha-dibenzylqlycine.
<223>
```

```
<220>
<221>
       misc_feature
<222>
      (6)..(6)
<223> Xaa in position six denotes C-alpha, alpha-dipropylglycine.
<220>
<221> misc feature
<222> (7)..(7)
<223> Lys in position seven is in amide form.
<400> 6
Lys Xaa Val Xaa Phe Xaa Lys
<210>
      7
<211> 6
<212>
      PRT
<213>
     Artificial sequence
<220>
<223> Designed peptide. This is an engineered modification of SEQ
ID
       NO: 3, which is in turn derived from Homo sapiens.
<220>
<221> misc feature
<222> (2)..(2)
<223> Xaa in position two denotes C-alpha, alpha-diisobutylglycine.
<220>
<221> misc feature
<222> (4)..(4)
<223> Xaa in position four denotes C-alpha, alpha-dibenzylglycine.
<220>
     misc feature
<221>
<222>
      (6)..(6)
      Xaa in position six denotes C-alpha, alpha-dibenzylglycine
<223>
amide.
<400> 7
Lys Xaa Val Xaa Phe Xaa
                5
```

```
<210>
<211>
       8
<212>
      PRT
      Artificial sequence
<213>
<220>
<223>
       Designed peptide. This is an engineered modification of SEQ
ID
       NO: 3, which is in turn derived from Homo sapiens.
<220>
<221>
      misc feature
<222>
      (2)..(2)
       Xaa in position two denotes C-alpha, alpha-dipropylglycine.
<223>
<220>
<221>
      misc_feature
<222>
      (4)..(4)
       Xaa in position four denotes C-alpha, alpha-dipropylglycine.
<223>
<220>
<221>
      misc_feature
<222>
      (6)..(6)
       Xaa in position six denotes C-alpha, alpha-dipropylglycine.
<223>
<220>
<221>
      misc feature
<222>
      (8)..(8)
<223>
       Glu in position 8 is in amide form.
<400>
Lys Xaa Val Xaa Thr Xaa Val Glu
<210>
       9
<211>
       5
<212>
      PRT
      Homo sapiens
<213>
<400>
Phe Leu Val His Ser
                5
<210> 10
```

```
<211>
      PRT
<212>
<213> Homo sapiens
<400>
      10
Asn Phe Leu Val His
                5
<210>
      11
<211>
       6
<212>
      PRT
<213>
      Homo sapiens
<400> 11
Asn Phe Gly Ala Ile Leu
<210>
      12
<211>
      9
<212>
      PRT
<213>
      Homo sapiens
<400>
      12
Val Gly Gly Ala Val Val Thr Gly Val
<210>
      13
<211>
       14
<212>
      PRT
<213>
      Homo sapiens
<400>
      13
Val Asn Ile Thr Ile Lys Gln His Thr Val Thr Thr Thr
                5
1
                                    10
<210>
      14
```

<211>

<212> PRT

6

<213> Homo sapiens

<400> 14

Leu Ala Asn Phe Leu Val

1 5

<210> 15

<211> 6

<212> PRT

<213> Homo sapiens

<400> 15

Phe Leu Val His Ser Ser

1 5

<210> 16

<211> 4

<212> PRT

<213> Homo sapiens

<400> 16

Ala Gly Asp Val

1

```
<210> 17
<211> 6
<212>
      PRT
<213> Artificial sequence
<220>
<223> Designed peptide. This is an engineered modification of SEQ
ID
       NO: 3, which is in turn derived from Homo sapiens.
<220>
<221> misc feature
<222> (2)..(2)
      Xaa in position two denotes C-alpha, alpha-diisobutylglycine.
<223>
<220>
<221> misc feature
      (4)..(4)
<222>
<223> Xaa in position four denotes C-alpha, alpha-dibenzylglycine.
<220>
<221> misc feature
<222> (6)..(6)
<223> Lys in position six is in amide form.
<400> 17
Lys Xaa Val Xaa Phe Lys
1
                5
```